E. Bria

International tailored chemotherapy adjuvant trial: ITACA trial.

C. Schumann, V. Torri, M. Papotti, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

G. Ceresoli, V. Vavassori, E. D'Argento, 2021, ESMO open.

Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis

A. Palazzo, C. Ciccarese, R. Iacovelli, 2023, ESMO open.

Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors

A. Marchetti, F. Mucilli, S. Novello, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities

G. Fontanini, U. Pastorino, A. Mafficini, 2021, ESMO open.

Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit

R. Gralla, F. Cognetti, D. Giannarelli, 2005 .

Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality

F. Cognetti, P. Carlini, D. Giannarelli, 2005 .

EP02.04-001 Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-Positive NSCLC: ALNEO Phase II Trial (GOIRC-01-2020)

D. Galetta, F. Mazzoni, L. Boni, 2022, Journal of Thoracic Oncology.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Comparing two methods of meta-analysis in clinical research - individual patient data-based (IPD) and literature-based abstracted data (AD) methods: Analyzing five oncology issues involving more than 10,000 patients in randomized clinical trials (RCTs)

R. Gralla, D. Giannarelli, H. Raftopoulos, 2007 .

Chemotherapy Rechallenge or Reintroduction compared to Regorafenib or Trifluridine/Tipiracil for pretreated metastatic colorectal cancer patients: a PROpensity ScorE analysis of tReatment beYond secoNd line (PROSERpYNa Study)

M. Calegari, G. Tortora, F. Camarda, 2024, Clinical Colorectal Cancer.